Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The De-Label Program Expansion
NCT06823154Phase 1Active, not recruiting
- Sponsor
- SickKids
- Start
- Nov 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amoxicillin in beta-lactam allergy (2 arms), sponsored by SickKids. Primary endpoint: Proportion of patients delabeled among those given the oral provocation challenge at 2 weeks. Started Nov 2023; status: active, not recruiting.
02
Drugs
amoxicillin
03
Conditions
beta-lactam allergy
Beyond the preview
Go deeper on NCT06823154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823154.